This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heer, K. Articles by Kerin, M. J. Search for Related Content PubMed PubMed Citation Articles by Heer, K. Articles by Kerin, M. J.

Serum Vascular Endothelial Growth Factor in Breast Cancer

Its Relation with Cancer Type and Estrogen Receptor Status¹

Academic Surgical Unit, University of Hull and Department of Pathology, Castle Hill Hospital, Cottingham, East Yorkshire HU16 5JQ, United Kingdom

Purpose: Angiogenesis is essential for tumor growth. Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. In breast cancer, tumor VEGF has been shown to have a good correlation with relapse-free survival. The aim of this study was to determine the relation of serum VEGF levels to the various indices of breast cancer and known tumor markers carcinoembryonic antigen and CA15.3.

Experimental Design: Preoperative serum VEGF levels were determined in 200 women with breast cancer and compared with serum VEGF levels in 88 healthy female controls.

Results: The serum VEGF levels of the cancer patients as a group were significantly elevated compared with those of the controls (P < 0.0005). VEGF levels were elevated in patients with invasive cancer of ductal/no specific type, ductal carcinoma in situ, and estrogen receptor (ER)-positive tumors. Patients with lobular carcinoma and ER-negative tumors had serum VEGF levels comparable with those in the controls. VEGF was more sensitive than CA15.3 and carcinoembryonic antigen in detecting breast cancer.

Conclusions: Preoperative serum VEGF detects breast cancer with a sensitivity of 62.1%. The relationship to cancer type and ER status may have future therapeutic implications. Additional long-term studies are required to determine the prognostic significance of serum VEGF.

This article has been cited by other articles:

				M. J. Ellis, Y. Tao, O. Young, S. White, A. D. Proia, J. Murray, L. Renshaw, D. Faratian, J. Thomas, M. Dowsett, et al. Estrogen-Independent Proliferation Is Present in Estrogen-Receptor HER2-Positive Primary Breast Cancer After Neoadjuvant Letrozole J. Clin. Oncol., July 1, 2006; 24(19): 3019 - 3025. [Abstract] [Full Text] [PDF]

				L. Mercatali, V. Valenti, D. Calistri, S. Calpona, G. Rosti, S. Folli, M. Gaudio, G. L. Frassineti, D. Amadori, and E. Flamini RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients Ann. Onc., March 1, 2006; 17(3): 424 - 428. [Abstract] [Full Text] [PDF]

				D. Fuckar, A. Dekanic, S. Stifter, E. Mustac, M. Krstulja, F. Dobrila, and N. Jonjic VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer International Journal of Surgical Pathology, January 1, 2006; 14(1): 49 - 55. [Abstract] [PDF]

				H. M. W. Verheul and H. M. Pinedo The Importance of Platelet Counts and Their Contents in Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3219 - 3221. [Full Text] [PDF]

				C. E. Murphy, M. R. J. Lansdown, V. Speirs, and P. J. Carder Correspondence re: K. Heer et al., Serum Vascular Endothelial Growth Factor in Breast Cancer: Its Relation with Cancer Type and Estrogen Receptor Status. Clin. Cancer Res., 7: 3491-3494, 2001. Clin. Cancer Res., August 1, 2003; 9(9): 3514 - 3514. [Full Text] [PDF]